Phase 1
Booster Vaccination After ~7 Years Resulted in 600-fold Increase in Antibody Response
Santhera Pharmaceuticals announces the start of a Phase Ib/IIa multiple ascending dose (MAD) trial with POL6014 in patients with cystic fibrosis (CF).
Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announces that data from a phase I study assessing the safety and tolerability of its lead drug candidate SNF472 in haemodialysis patients has been published in the British Journal of Clinical Pharmacology.
Routine corticosteroid treatment correlates with increased mortality and decreased Traumakine efficacy
ASLAN Pharmaceuticals today announced the presentation of new data from an ongoing phase 1 study to determine the safety, tolerability and maximum tolerated dose (MTD) of varlitinib in combination with oxaliplatin and capecitabine (COX) or oxaliplatin and 5-FU (FOL) in advanced solid tumours.
Hutchison China MediTech Limited has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in combination with azacitidine, an approved nucleoside metabolic inhibitor, in elderly patients with acute myeloid leukemia (“AML”) in China.
Bioavailability significantly higher than with oral administration
Proteostasis Therapeutics announced positive preliminary data from its ongoing Phase I clinical trial of PTI-808 and PTI-801 in cystic fibrosis (CF). Despite it being an early-stage trial and preliminary data, company shares exploded upward by 301 percent, with more than 44 million shares trading hands.
KB103 is Krystal’s first “off-the-shelf”, topical, gene therapy candidate to treat patients suffering from Dystrophic Epidermolysis Bullosa.
MaxCyte announced today that the first patient has been dosed in its Phase I dose-escalation clinical trial in the United States with the Company’s lead wholly-owned chimeric antigen receptor (CAR) therapeutic candidate, MCY-M11.
PRESS RELEASES